Key facts
- Global drugmakers are committing approximately $500 billion to expand U.S. manufacturing and research operations.
- Investments aim to strengthen infrastructure and reduce supply chain vulnerabilities.
- Pfizer will invest $70 billion in R&D and domestic manufacturing, receiving a three-year exemption from pharmaceutical tariffs.
- Eli Lilly plans to build six new U.S. plants as part of at least a $27 billion investment.
- Johnson & Johnson will increase U.S. investments by 25% to $55 billion over four years.
- Roche is investing $50 billion in the U.S. over five years, with an additional $550 million for diagnostics manufacturing.
- AstraZeneca will invest $50 billion in U.S. manufacturing by 2030.
Global pharmaceutical companies are significantly increasing their presence and investments in the United States. Collectively, major drugmakers like Pfizer, GSK, Eli Lilly, Johnson & Johnson, Roche, and AstraZeneca have announced plans to invest approximately $500 billion to expand their manufacturing and research operations.
These substantial commitments are aimed at strengthening domestic infrastructure, mitigating supply chain vulnerabilities, and reassuring investors. Pfizer, for instance, has agreed to invest $70 billion in U.S. research and development and manufacturing, securing a three-year exemption from pharmaceutical tariffs in return.
GSK plans to invest $30 billion in U.S. research and development and supply chain infrastructure over a five-year period. Eli Lilly intends to construct six new plants in the United States, with a previously announced plan to spend at least $27 billion on four U.S. facilities.
Johnson & Johnson will raise its U.S. investments by 25% to a total of $55 billion over the next four years, including plans for four new plants. Roche announced a $50 billion investment in the U.S. over five years, along with an additional $550 million to expand its diagnostics manufacturing hub across several states. AstraZeneca will invest $50 billion in U.S. manufacturing by 2030, including a new drug substance facility in Virginia.